Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1993 Aug;143(2):453–463.

Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury.

A Seekamp 1, J S Warren 1, D G Remick 1, G O Till 1, P A Ward 1
PMCID: PMC1887029  PMID: 7688184

Abstract

Ischemia in rat hind limbs followed by reperfusion results in local as well as remote organ (lung) injury characterized by increased vascular permeability (125I-labeled bovine serum albumin leakage) and hemorrhage (51Cr-labeled rat erythrocytes extravasation) in skeletal muscle and lung, together with an associated increased tissue content of myeloperoxidase, reflecting neutrophil accumulation. Within 60 minutes of reperfusion following ischemia, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and IL-6 plasma levels increased significantly, reaching maximum levels after 2 hours of reperfusion. Polyclonal antibodies to TNF-alpha and IL-1 provided significant protection against vascular injury in both muscle and lung. These results were confirmed by the use of soluble TNF-alpha receptor and IL-1 receptor antagonist. In rat lungs following ischemia and reperfusion, there was immunohistochemical evidence of E-selectin expression in the lung vasculature; this expression was blocked by treatment of animals with anti-TNF-alpha. These data indicate that both local (hind limb) and remote (lung) organ injury after ischemia/reperfusion requires participation of TNF-alpha and IL-1. The cytokines may, in part, be involved in the up-regulation of endothelial adhesion molecules.

Full text

PDF
454

Images in this article

459Figure 7
on p.459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., De Groot E. R., Schaap O. L., Lansdorp P. M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. doi: 10.1002/eji.1830171004. [DOI] [PubMed] [Google Scholar]
  2. Alexander H. R., Doherty G. M., Venzon D. J., Merino M. J., Fraker D. L., Norton J. A. Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery. 1992 Aug;112(2):188–194. [PubMed] [Google Scholar]
  3. Allan G., Bhattacherjee P., Brook C. D., Read N. G., Parke A. J. Myeloperoxidase activity as a quantitative marker of polymorphonuclear leukocyte accumulation into an experimental myocardial infarct--the effect of ibuprofen on infarct size and polymorphonuclear leukocyte accumulation. J Cardiovasc Pharmacol. 1985 Nov-Dec;7(6):1154–1160. doi: 10.1097/00005344-198511000-00022. [DOI] [PubMed] [Google Scholar]
  4. Anner H., Kaufman R. P., Jr, Kobzik L., Valeri C. R., Shepro D., Hechtman H. B. Pulmonary leukosequestration induced by hind limb ischemia. Ann Surg. 1987 Aug;206(2):162–167. doi: 10.1097/00000658-198708000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Arfors K. E., Lundberg C., Lindbom L., Lundberg K., Beatty P. G., Harlan J. M. A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo. Blood. 1987 Jan;69(1):338–340. [PubMed] [Google Scholar]
  6. Ascer E., Mohan C., Gennaro M., Cupo S. Interleukin-1 and thromboxane release after skeletal muscle ischemia and reperfusion. Ann Vasc Surg. 1992 Jan;6(1):69–73. doi: 10.1007/BF02000671. [DOI] [PubMed] [Google Scholar]
  7. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  8. Bevilacqua M. P., Pober J. S., Mendrick D. L., Cotran R. S., Gimbrone M. A., Jr Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9238–9242. doi: 10.1073/pnas.84.24.9238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brown J. M., White C. W., Terada L. S., Grosso M. A., Shanley P. F., Mulvin D. W., Banerjee A., Whitman G. J., Harken A. H., Repine J. E. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5026–5030. doi: 10.1073/pnas.87.13.5026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Camussi G., Bussolino F., Salvidio G., Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med. 1987 Nov 1;166(5):1390–1404. doi: 10.1084/jem.166.5.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Caty M. G., Guice K. S., Oldham K. T., Remick D. G., Kunkel S. I. Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury. Ann Surg. 1990 Dec;212(6):694–700. doi: 10.1097/00000658-199012000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Colletti L. M., Remick D. G., Burtch G. D., Kunkel S. L., Strieter R. M., Campbell D. A., Jr Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest. 1990 Jun;85(6):1936–1943. doi: 10.1172/JCI114656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cybulsky M. I., Chan M. K., Movat H. Z. Acute inflammation and microthrombosis induced by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram-negative infection. Lab Invest. 1988 Apr;58(4):365–378. [PubMed] [Google Scholar]
  14. Dinarello C. A. Biology of interleukin 1. FASEB J. 1988 Feb;2(2):108–115. [PubMed] [Google Scholar]
  15. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  16. Entman M. L., Youker K., Shappell S. B., Siegel C., Rothlein R., Dreyer W. J., Schmalstieg F. C., Smith C. W. Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. J Clin Invest. 1990 May;85(5):1497–1506. doi: 10.1172/JCI114596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ferrante A., Nandoskar M., Walz A., Goh D. H., Kowanko I. C. Effects of tumour necrosis factor alpha and interleukin-1 alpha and beta on human neutrophil migration, respiratory burst and degranulation. Int Arch Allergy Appl Immunol. 1988;86(1):82–91. doi: 10.1159/000234610. [DOI] [PubMed] [Google Scholar]
  18. Fong Y., Moldawer L. L., Marano M., Wei H., Tatter S. B., Clarick R. H., Santhanam U., Sherris D., May L. T., Sehgal P. B. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol. 1989 Apr 1;142(7):2321–2324. [PubMed] [Google Scholar]
  19. Gamble J. R., Harlan J. M., Klebanoff S. J., Vadas M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667–8671. doi: 10.1073/pnas.82.24.8667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251–7255. doi: 10.1073/pnas.84.20.7251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Girardin E., Grau G. E., Dayer J. M., Roux-Lombard P., Lambert P. H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988 Aug 18;319(7):397–400. doi: 10.1056/NEJM198808183190703. [DOI] [PubMed] [Google Scholar]
  22. Hannum C. H., Wilcox C. J., Arend W. P., Joslin F. G., Dripps D. J., Heimdal P. L., Armes L. G., Sommer A., Eisenberg S. P., Thompson R. C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990 Jan 25;343(6256):336–340. doi: 10.1038/343336a0. [DOI] [PubMed] [Google Scholar]
  23. Horvath C. J., Ferro T. J., Jesmok G., Malik A. B. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9219–9223. doi: 10.1073/pnas.85.23.9219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kawakami M., Ishibashi S., Ogawa H., Murase T., Takaku F., Shibata S. Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells. Biochem Biophys Res Commun. 1986 Dec 15;141(2):482–487. doi: 10.1016/s0006-291x(86)80198-x. [DOI] [PubMed] [Google Scholar]
  25. Kirnbauer R., Charvat B., Schauer E., Köck A., Urbanski A., Förster E., Neuner P., Assmann I., Luger T. A., Schwarz T. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF beta, and UVB light. J Invest Dermatol. 1992 Mar;98(3):320–326. doi: 10.1111/1523-1747.ep12499793. [DOI] [PubMed] [Google Scholar]
  26. Korthuis R. J., Grisham M. B., Granger D. N. Leukocyte depletion attenuates vascular injury in postischemic skeletal muscle. Am J Physiol. 1988 May;254(5 Pt 2):H823–H827. doi: 10.1152/ajpheart.1988.254.5.H823. [DOI] [PubMed] [Google Scholar]
  27. Lefer A. M., Tsao P., Aoki N., Palladino M. A., Jr Mediation of cardioprotection by transforming growth factor-beta. Science. 1990 Jul 6;249(4964):61–64. doi: 10.1126/science.2164258. [DOI] [PubMed] [Google Scholar]
  28. Lin H., Chensue S. W., Strieter R. M., Remick D. G., Gallagher K. P., Bolling S. F., Kunkel S. L. Antibodies against tumor necrosis factor prolong cardiac allograft survival in the rat. J Heart Lung Transplant. 1992 Mar-Apr;11(2 Pt 1):330–335. [PubMed] [Google Scholar]
  29. Mathison J. C., Wolfson E., Ulevitch R. J. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988 Jun;81(6):1925–1937. doi: 10.1172/JCI113540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Maury C. P., Teppo A. M. Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection. J Exp Med. 1987 Oct 1;166(4):1132–1137. doi: 10.1084/jem.166.4.1132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. May L. T., Ghrayeb J., Santhanam U., Tatter S. B., Sthoeger Z., Helfgott D. C., Chiorazzi N., Grieninger G., Sehgal P. B. Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem. 1988 Jun 5;263(16):7760–7766. [PubMed] [Google Scholar]
  32. Minami M., Kuraishi Y., Yabuuchi K., Yamazaki A., Satoh M. Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. J Neurochem. 1992 Jan;58(1):390–392. doi: 10.1111/j.1471-4159.1992.tb09324.x. [DOI] [PubMed] [Google Scholar]
  33. Mulligan M. S., Varani J., Dame M. K., Lane C. L., Smith C. W., Anderson D. C., Ward P. A. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest. 1991 Oct;88(4):1396–1406. doi: 10.1172/JCI115446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mulligan M. S., Varani J., Warren J. S., Till G. O., Smith C. W., Anderson D. C., Todd R. F., 3rd, Ward P. A. Roles of beta 2 integrins of rat neutrophils in complement- and oxygen radical-mediated acute inflammatory injury. J Immunol. 1992 Mar 15;148(6):1847–1857. [PubMed] [Google Scholar]
  35. Mulligan M. S., Ward P. A. Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1. J Immunol. 1992 Jul 1;149(1):331–339. [PubMed] [Google Scholar]
  36. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Nijsten M. W., de Groot E. R., ten Duis H. J., Klasen H. J., Hack C. E., Aarden L. A. Serum levels of interleukin-6 and acute phase responses. Lancet. 1987 Oct 17;2(8564):921–921. doi: 10.1016/s0140-6736(87)91413-9. [DOI] [PubMed] [Google Scholar]
  38. Okusawa S., Gelfand J. A., Ikejima T., Connolly R. J., Dinarello C. A. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988 Apr;81(4):1162–1172. doi: 10.1172/JCI113431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Pogrebniak H., Matthews W., Mitchell J., Russo A., Samuni A., Pass H. Spin trap protection from tumor necrosis factor cytotoxicity. J Surg Res. 1991 May;50(5):469–474. doi: 10.1016/0022-4804(91)90026-i. [DOI] [PubMed] [Google Scholar]
  40. Pohlman T. H., Stanness K. A., Beatty P. G., Ochs H. D., Harlan J. M. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol. 1986 Jun 15;136(12):4548–4553. [PubMed] [Google Scholar]
  41. Remick D. G., Kunkel R. G., Larrick J. W., Kunkel S. L. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest. 1987 Jun;56(6):583–590. [PubMed] [Google Scholar]
  42. Rokita H., Mackiewicz M., Koj A. Acute phase response to recombinant interleukin-6 and macrophage- and fibroblast-derived crude cytokine preparations in primary cultures of mouse hepatocytes. Cell Biochem Funct. 1989 Oct;7(4):257–262. doi: 10.1002/cbf.290070404. [DOI] [PubMed] [Google Scholar]
  43. Ruff M. R., Gifford G. E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol. 1980 Oct;125(4):1671–1677. [PubMed] [Google Scholar]
  44. Sakr M., Zetti G., McClain C., Gavaler J., Nalesnik M., Todo S., Starzl T., Van Thiel D. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation. 1992 May;53(5):987–991. doi: 10.1097/00007890-199205000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Satomi N., Sakurai A., Haranaka R., Haranaka K. Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor. J Biol Response Mod. 1988 Feb;7(1):54–64. [PubMed] [Google Scholar]
  46. Seekamp A., Mulligan M. S., Till G. O., Ward P. A. Requirements for neutrophil products and L-arginine in ischemia-reperfusion injury. Am J Pathol. 1993 Apr;142(4):1217–1226. [PMC free article] [PubMed] [Google Scholar]
  47. Sehgal P. B., Helfgott D. C., Santhanam U., Tatter S. B., Clarick R. H., Ghrayeb J., May L. T. Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the beta 2-interferon/hepatocyte-stimulating factor/interleukin 6 gene in virus-infected human fibroblasts. J Exp Med. 1988 Jun 1;167(6):1951–1956. doi: 10.1084/jem.167.6.1951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Strieter R. M., Kunkel S. L., Showell H. J., Remick D. G., Phan S. H., Ward P. A., Marks R. M. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science. 1989 Mar 17;243(4897):1467–1469. doi: 10.1126/science.2648570. [DOI] [PubMed] [Google Scholar]
  49. Tosato G., Seamon K. B., Goldman N. D., Sehgal P. B., May L. T., Washington G. C., Jones K. D., Pike S. E. Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science. 1988 Jan 29;239(4839):502–504. doi: 10.1126/science.2829354. [DOI] [PubMed] [Google Scholar]
  50. Waage A., Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med. 1988 Jun 1;167(6):1987–1992. doi: 10.1084/jem.167.6.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  52. Wakabayashi G., Gelfand J. A., Burke J. F., Thompson R. C., Dinarello C. A. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991 Mar 1;5(3):338–343. doi: 10.1096/fasebj.5.3.1825816. [DOI] [PubMed] [Google Scholar]
  53. Warren J. S. Disparate roles for TNF in the pathogenesis of acute immune complex alveolitis and dermal vasculitis. Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 1):249–259. doi: 10.1016/s0090-1229(05)80028-5. [DOI] [PubMed] [Google Scholar]
  54. Warren J. S. Intrapulmonary interleukin 1 mediates acute immune complex alveolitis in the rat. Biochem Biophys Res Commun. 1991 Mar 15;175(2):604–610. doi: 10.1016/0006-291x(91)91608-f. [DOI] [PubMed] [Google Scholar]
  55. Warren J. S., Yabroff K. R., Remick D. G., Kunkel S. L., Chensue S. W., Kunkel R. G., Johnson K. J., Ward P. A. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest. 1989 Dec;84(6):1873–1882. doi: 10.1172/JCI114374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Welbourn R., Goldman G., O'Riordain M., Lindsay T. F., Paterson I. S., Kobzik L., Valeri C. R., Shepro D., Hechtman H. B. Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. J Appl Physiol (1985) 1991 Jun;70(6):2645–2649. doi: 10.1152/jappl.1991.70.6.2645. [DOI] [PubMed] [Google Scholar]
  57. Youker K., Smith C. W., Anderson D. C., Miller D., Michael L. H., Rossen R. D., Entman M. L. Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion. J Clin Invest. 1992 Feb;89(2):602–609. doi: 10.1172/JCI115626. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES